Truist reiterates Buy on American Healthcare REIT stock after earnings
Truist reiterated a Buy rating and $61 price target on American Healthcare REIT (AHR) after its earnings beat estimates, driven by senior housing revenue growth and lower expenses. The stock is up 20.88% YTD, but some analysts consider it overvalued. KeyBanc raised its target to $68, while Citizens maintained a Market Outperform rating with a $65 target. Raymond James initiated coverage with a Strong Buy, citing strong acquisition activity and partnerships.
How this was made
The 30-second read
Why it matters
Analyst upgrades from Truist, KeyBanc, Citizens, and Raymond James provide fresh bullish sentiment and new price targets ranging $61‑$68.
Market read
Earnings beat and multiple analyst upgrades create a short‑term buying opportunity for AHR.
What to watch
Potential headwinds from rising interest rates could affect future acquisition financing.
Background
American Healthcare REIT (AHR) posted Q3 normalized FFO of $0.54 per share, GAAP EPS $0.16, and revenue $674.25 million, beating estimates.
Ticker impact
Truist reiterated a Buy rating and raised the price target to $61 after American Healthcare REIT reported strong Q3 earnings and higher FFO.
likely upward pressure as investors price in the higher target and strong senior‑housing performance
Analyst upgrades and a new $61 target provide a clear catalyst for buying pressure.
Market effects
Strong senior‑housing results may lift other REITs focused on healthcare and senior living.
U.S. REIT sector could see modest gains in early trade.
Limited to U.S. equity markets.
Counterpoint
The stock may be overvalued relative to fair‑value estimates, risking a pull‑back.
Key entities
- analystTruist Securities
Reiterated Buy rating and set $61 price target.
- analystKeyBanc
Raised price target to $68.
